INO
INOVIO PHARMACEUTICALS, INC.
+0.08 (+7.03%)1.23USD1.5M成交股數127M市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-10下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 0.00-100% | 0.00-100% | 0.00 | 0.00-100% | 65K | 117K-70% | 0.00-100% | 101K-12% | 0.00 | 388K | 226K | 115K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 10.8M | 14.1M | 13.3M | 14.5M | 16.1M | 12.9M | 18.7M | 23.1M | 20.9M | 15.5M | 23.7M | 30.2M |
| 銷售管理費用 | 7.8M | 7.9M | 7.9M | 8.6M | 9.0M | 7.6M | 8.6M | 10.2M | 10.6M | 9.9M | 13.5M | 13.9M |
| 營業利益 | −18.6M-26% | −21.9M+8% | −21.2M-22% | −23.1M-30% | −25.1M-20% | −20.4M-43% | −27.3M-26% | −33.2M-24% | −31.5M | −35.6M | −37.0M | −44.0M |
| 營業利益率 | – | – | – | – | -38,337.0% | -17,410.8% | – | -32,945.9% | – | -9,152.6% | -16,392.0% | -38,238.2% |
| 稅後淨利 | −6.0M-69% | −19.7M+3% | −45.5M+81% | −23.5M-27% | −19.7M-35% | −19.1M-44% | −25.2M-29% | −32.2M-21% | −30.5M | −33.9M | −35.5M | −40.6M |
| 淨利率 | – | – | – | – | -30,140.5% | -16,349.2% | – | -31,993.3% | – | -8,734.8% | -15,725.3% | -35,364.8% |
| 稀釋 EPS | -0.07-86% | -0.28-50% | -0.87-2% | -0.61-49% | -0.51-61% | -0.56-63% | -0.89-45% | -1.19-37% | -1.31 | -1.52 | -1.61 | -1.89 |
| 稀釋股數 | 81.6M | 69.1M | 52.2M | 38.8M | 38.6M | 27.2M | 28.1M | 27.2M | 23.3M | 22.4M | 22.0M | 21.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 31.5M | 26.3M | 36.6M | 24.4M | 39.9M | 65.8M | 21.7M | 34.4M | 19.6M | 18.8M | 52.7M | 28.2M |
| 應收帳款 | – | – | 979K | 840K | 1.3M | 1.2M | 1.9M | 1.8M | 2.6M | – | – | 73K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 49.4M | 49.8M | 69.4M | 68.2M | 87.3M | 113M | 107M | 134M | 129M | 193M | 233M | 267M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 45.0M | 43.7M | 77.1M | 39.7M | 36.0M | 44.7M | 33.5M | 37.1M | 34.7M | 54.9M | 63.7M | 67.4M |
| 股東權益 | 4.4M | 6.1M | −7.7M | 28.5M | 51.3M | 68.5M | 73.5M | 96.7M | 94.4M | 138M | 169M | 199M |
| 負債比 | 91.1% | 87.8% | 111.1% | 58.2% | 41.3% | 39.5% | 31.3% | 27.7% | 26.9% | 28.5% | 27.3% | 25.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −21.6M | – | – | −26.9M-7% | – | – | – | −28.8M | – | – | −36.7M |
| 資本支出 | – | 0.00 | – | – | 59K | – | – | – | 36K | – | – | 297K |
| 自由現金流 | – | −21.6M | – | – | −26.9M-6% | – | – | – | −28.8M | – | – | −37.0M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | -41,218.5% | – | – | – | – | – | – | -32,156.3% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 65K
| Reportable Segments | 65K | 100.0% | -70.0% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 65K | -70.0% | −85.0M | -130,082.8% | -1.81 | −88.9M |
| FY2024 | 218K | -73.8% | −107M | -49,137.6% | -3.95 | −105M |
| FY2023 | 832K | -91.9% | −135M | -16,225.8% | -6.09 | −125M |
| FY2022 | 10.3M | +478.2% | −280M | -2,726.7% | -14.07 | −217M |
| FY2021 | 1.8M | -76.1% | −304M | -17,109.9% | -17.45 | −217M |
| FY2020 | 7.4M | +80.2% | −166M | -2,245.4% | -1.07 | −179M |
| FY2019 | 4.1M | -86.5% | −119M | -2,902.8% | -1.21 | −98.8M |
| FY2018 | 30.5M | – | −97.0M | -318.1% | -1.05 | −75.6M |